Use-Results Survey for ORENCIA® Subcutaneous Injection 125mg Syringe 1mL
This trial is active, not recruiting.
|Collaborator||Ono Pharmaceutical Co. Ltd|
|Start date||September 2013|
|End date||September 2016|
|Trial size||370 participants|
|Trial identifier||NCT02600455, IM101-515|
The purpose of this study to collect information on the safety, especially localized injection site reactions, and efficacy of ORENCIA Subcutaneous Injection 125mg Syringe 1mL in patients with rheumatoid arthritis.
Patients who are treated with ORENCIA according to the approved indications, and dosage and administration
Safety measured by number of Adverse events and laboratory abnormalities associated with adverse events
time frame: 24 weeks
Male or female participants at least 18 years old.
Inclusion Criteria: - Patients who are beginning to receive the treatment with ORENCIA Subcutaneous Injection 125mg Syringe 1mL under the approved indications, dosage, and administration
|Official title||Outline of Use-Results Survey for ORENCIA® Subcutaneous Injection 125mg Syringe 1mL|
Call for more information